Chronic linaclotide treatment reduces colitis-induced neuroplasticity and reverses persistent bladder dysfunction
Authors:
- Luke GrundyLGLuke Grundy
- Andrea M. HarringtonAHAndrea M. Harrington
- Joel CastroJCJoel Castro
- Sonia Garcia-CaraballoSGSonia Garcia-Caraballo
- Annemie DeiterenADAnnemie Deiteren
- Jessica MaddernJMJessica Maddern
- Grigori Y. RychkovGRGrigori Y. Rychkov
- Pei GePGPei Ge
- Stefanie PetersSPStefanie Peters
- Robert FeilRFRobert Feil
- Andre GhettiAGAndre Ghetti
- 4 October 2018
- journal article
- research article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 3 (19)
Abstract
Irritable bowel syndrome (IBS) patients suffer from chronic abdominal pain and extraintestinal comorbidities, including overactive bladder (OAB) and interstitial cystitis/painful bladder syndrome (IC-PBS). Mechanistic understanding of the cause and time course of these comorbid symptoms is lacking, as are clinical treatments. Here, we report that colitis triggers hypersensitivity of colonic afferents, neuroplasticity of spinal cord circuits, and chronic abdominal pain, which persists after inflammation. Subsequently, and in the absence of bladder pathology, colonic hypersensitivity induces persistent hypersensitivity of bladder afferent pathways, resulting in bladder-voiding dysfunction, indicative of OAB/IC-PBS. Daily administration of linaclotide, a guanylate cyclase-C (GC-C) agonist that is restricted to and acts within the gastrointestinal tract, reverses colonic afferent hypersensitivity, reverses neuroplasticity-induced alterations in spinal circuitry, and alleviates chronic abdominal pain in mice. Intriguingly, daily linaclotide administration also reverses persistent bladder afferent hypersensitivity to mechanical and chemical stimuli and restores normal bladder voiding. Linaclotide itself does not inhibit bladder afferents, rather normalization of bladder function by daily linaclotide treatment occurs via indirect inhibition of bladder afferents via reduced nociceptive signaling from the colon. These data support the concepts that cross-organ sensitization underlies the development and maintenance of visceral comorbidities, while pharmaceutical treatments that inhibit colonic afferents may also improve urological symptoms through common sensory pathways.Keywords
Funding Information
- National Health and Medical Research Council of Australia (R.D Wright Biomedical Research Fellow (APP1126378 to S.M.B),NHMRC Australia Project Grants (#1083480,#1139366)
- National Health and Medical Research Council of Australia (#1140297 to S.M.B))
- Australian Research Council (Discovery Early Career Research Award (DE130100223 to A.M.H))
- Australian Research Council (Discovery Project (DP180101395 to A.M.H)
- Australian Research Council (S.M.B).)
- DFG (grant FOR 2060 (FE 438/5-2)
- DFG (FE 438/6-2 to R.F),the Fund for Science (to R.F)
This publication has 44 references indexed in Scilit:
- Lack of transient receptor potential vanilloid 1 channel modulates the development of neurogenic bladder dysfunction induced by cross-sensitization in afferent pathwaysJournal of Neuroinflammation, 2013
- Colonic inflammation up‐regulates voltage‐gated sodium channels in bladder sensory neurons via activation of peripheral transient potential vanilloid 1 receptorsNeurogastroenterology & Motility, 2012
- Up-regulation of brain-derived neurotrophic factor in primary afferent pathway regulates colon-to-bladder cross-sensitization in ratJournal of Neuroinflammation, 2012
- The Mechanoreceptor TRPV4 is Localized in Adherence Junctions of the Human Bladder Urothelium: A Morphological StudyJournal of Urology, 2011
- Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tractLife Sciences, 2010
- Design of fluorescence resonance energy transfer (FRET)-based cGMP indicators: a systematic approachBiochemical Journal, 2007
- Bladder afferent sensitivity in wild‐type and TRPV1 knockout miceThe Journal of Physiology, 2007
- Convergence of bladder and colon sensory innervation occurs at the primary afferent levelPain, 2007
- Microglia: a newly discovered role in visceral hypersensitivity?Neuron Glia Biology, 2006
- Mice Lacking the Guanylyl Cyclase C Receptor Are Resistant to STa-Induced Intestinal SecretionBiochemical and Biophysical Research Communications, 1997